meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
3
mHCC - 1st line (L1)
10
mHCC - 2nd line (L2)
2
lung cancer : non small cell (NSCLC)
5
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
pembrolizumab based treatment
pembrolizumab alone
versus all
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs atezolizumab based treatment
vs atezolizumab plus bevacizumab
vs non active control
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
table
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
click on circles to display study description...
powered by
vis.js Network